Primary hormonal therapy for prostate cancer: Experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center

Prostate Cancer and Prostatic Diseases

Volumn 5, Issue 2, 2002, Pages 152-158

  Koff, S G ^a,b   Connelly, R R ^b   Bauer, J J ^a,b   McLeod, D G ^a,b   Moul, J W ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

Hormonal therapy; Outcome; Prostate cancer; PSA

Indexed keywords

ALKALINE PHOSPHATASE; ANTIANDROGEN; GONADORELIN; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARMY; ARTICLE; CANCER CENTER; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; HEALTH CARE ACCESS; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICAL RECORD; METASTASIS; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; STATISTICAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; MIDDLE AGED; PROSTATE TUMOR; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; HOSPITALS, MILITARY; HUMAN; MALE; MIDDLE AGE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; HUMANS; MIDDLE AGED;

EID: 0035996417     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500551     Document Type: Article

References (16)

1. Cancer statistics
2. American Cancer Society guidelines for the early detection of cancer: Update of early detection guidelines for prostate, colorectal, and endometrial cancers
3. Treatment options for prostate cancer: Part I-stage, grade, PSA and changes in the 1990s
4. Contemporary hormonal management of advanced prostate cancer
5. Management of advanced/metastatic prostate cancer: 2000 updated
6. Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system
7. African-American ethnic background is an independent and negative predictor of survival in metastatic prostate cancer
8. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate
9. Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomized trials with 3283 deaths in 5710 patients
10. Effect of age and race on the survival of men with prostate cancer in the metropolitan Detroit tri-county area, 1973 to 1987
11. A controlled trial of leuprolide with and without flutamide in prostate cancer
12. Maximal androgen blockage: Final analysis of EORETC phase III trial 30853
13. Efficacy of the combination of nilutamide plus orchiectomy in patients with metastatic prostate cancer: A meta-analysis of seven randomized, double-blind trials (1056 patients)
14. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multi-national double-blind randomized trial
15. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
16. Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens